In the rapidly evolving realm of stroke management, an exceptional advancement in artificial intelligence (AI) technology is ushering in a transformative epoch. Brainomix, a pioneer in the digital healthcare domain, has presented results from a groundbreaking study at the European Stroke Organization Conference (ESOC) that promise to recalibrate the benchmarks for stroke therapy. This comprehensive investigation, the largest of its kind to assess stroke AI software, spanned three years and encompassed over 83,000 stroke patients at 26 different sites. The findings are a testament to the significant impact of Brainomix’s flagship product, Brainomix 360 Stroke, on treatment methods in the United Kingdom, notably in enhancing the rates of thrombectomy—a vital intervention in managing severe strokes.
The study shone a light on a notable escalation in thrombectomy procedures at UK centers that implemented the Brainomix software. Facilities that assessed the technology reported an impressive 115% increase in thrombectomy rates, a figure that significantly eclipses the 65% rise seen at locations not using the software. This surge underscores the critical contribution of Brainomix 360 Stroke in expanding access to crucial mechanical thrombectomy treatments and delineates the software’s efficacy in improving both the frequency and timeliness of stroke interventions throughout England.
Dr. George Harston, the distinguished Chief Medical and Innovation Officer at Brainomix, has expressed great optimism regarding the study’s results. The data not only reflects enhanced treatment outcomes and accelerated treatment timelines but also underscores the software’s capacity to refine patient care pathways and amplify treatment efficiencies. Such compelling evidence supports the notion that Brainomix’s AI platform is a game-changer in stroke care.
The integration of Brainomix 360 Stroke was linked with a 50% higher increase in the number of patients undergoing mechanical thrombectomy, highlighting the software’s essential role in making critical stroke interventions more accessible. Furthermore, the elevated thrombectomy rates are anticipated to yield considerable economic benefits for the UK, with projected savings of approximately £30 million, illustrating the financial merit of incorporating AI technology into stroke treatment.
The trial, conducted independently by the UK government and in collaboration with Health Innovation Oxford & Thames Valley, juxtaposed data from sites using the software with those that did not, unveiling the palpable advantages of employing Brainomix’s AI solution in stroke care settings. The study’s principal investigator, Kiruba Nagaratnam, recognized the software’s impact in diminishing Door-In-Door-Out (DIDO) time, an essential measure for evaluating stroke treatment efficacy.
Moreover, the far-reaching effect of Brainomix’s stroke AI platform was evident in its association with reduced treatment times, shaving off an impressive 49 minutes. This marked decrease in the duration of treatment exemplifies the software’s proficiency in expediting stroke care delivery and bolstering patient outcomes.
The extraordinary influence of Brainomix 360 Stroke was not limited to individual patient care but also extended to collaborative care models within stroke networks, demonstrating the software’s versatility and scalability in a variety of healthcare environments. At the Royal Berkshire Hospital, the software’s implementation resulted in a tripling of stroke patients achieving functional independence, a significant achievement that emphasizes the vital role of AI technology in revolutionizing stroke care approaches and enhancing patients’ quality of life.
Announced at the ESOC in Basel, Switzerland, the study highlighted the substantial improvements in patient outcomes at the participating sites, with the Royal Berkshire Hospital achieving notable progress in patient care. A threefold increase in stroke patients attaining functional independence at this hospital was a standout point, with the association between the software and faster treatment times solidifying its position as an innovative instrument in stroke management.
Brainomix’s extensive real-world evaluation of its stroke AI software marks a decisive advancement in perfecting stroke care practices in the UK. Backed by reputable bodies such as Oxford HIN and the NHS AAC, the study’s rigorous assessment and corroboration of findings from a single site emphasize the potential of Brainomix’s AI software to refine stroke treatment protocols and optimize patient care pathways.
Looking to the future, the implications of this study are profound. The deployment of Brainomix’s AI technology is not only promising for enhancing access to life-saving treatments and ameliorating patient outcomes but also represents a significant stride in the efficiency and cost-effectiveness of stroke care. As Brainomix continues to spearhead innovations in AI technology for stroke treatment, a promising new chapter is unfolding. In this pioneering era, AI-driven solutions are poised to have a substantial impact on healthcare delivery, shining a beacon of hope for improved care and recovery for stroke patients across the globe.
